US biosim­i­lar 'void' spells trou­ble as bi­o­log­ic patent ex­pi­ra­tions loom, IQVIA re­port says

While 118 bi­o­log­ics are ex­pect­ed to lose patent pro­tec­tion in the US over the next decade, that $234 bil­lion op­por­tu­ni­ty for biosim­i­lar de­vel­op­ers may not …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER